Download the full article (PDF)
Cell-Based Assays for G Protein-Coupled Receptors (GPCRs)

G protein-coupled receptors and their signaling pathways

G protein–coupled receptors (GPCRs) represent one of the largest and most diverse families of membrane receptors in biology, responsible for detecting a wide variety of extracellular stimuli such as hormones, neurotransmitters, lipids, peptides, and sensory signals. Structurally, GPCRs share a common architecture of seven transmembrane α-helices connected by intracellular and extracellular loops, with an extracellular N-terminus and an intracellular C-terminus. Upon ligand binding, the receptor undergoes a conformational rearrangement that activates nearby heterotrimeric G proteins composed of α, β, and γ subunits. The Gα subunit exchanges GDP for GTP, dissociating from the βγ dimer, and both parts then interact with downstream effectors such as adenylyl cyclase, phospholipase C, or ion channels. These events initiate intracellular signaling cascades that regulate cellular metabolism, gene transcription, secretion, motility, and survival. Because of their broad physiological roles, GPCRs are the targets of roughly one-third of all approved drugs, including treatments for cardiovascular, neurological, and metabolic diseases. The signaling pathways triggered by GPCRs depend on which Gα subunit family they engage—Gs, Gi/o, Gq/11, or G12/13—each activating distinct second messenger systems. Gs-coupled receptors stimulate adenylyl cyclase to convert ATP into cyclic AMP (cAMP), which activates protein kinase A (PKA). PKA then phosphorylates numerous cytoplasmic and nuclear targets, including the transcription factor CREB, leading to altered gene expression. Gi/o-coupled receptors inhibit adenylyl cyclase, decreasing cAMP levels, but can also activate the MAPK/ERK and PI3K/AKT pathways via βγ subunits. Gq/11 proteins activate phospholipase Cβ (PLCβ), producing inositol trisphosphate (IP₃) and diacylglycerol (DAG); IP₃ mobilizes calcium from intracellular stores, while DAG activates protein kinase C (PKC). Through these diverse routes, GPCRs influence nearly every cellular process, allowing a single extracellular signal to produce context-specific outcomes depending on receptor subtype, cell type, and downstream effectors.
G Protein Effector ActivatedMessenger / Kinase PathwayExample Receptor
GsAdenylyl cyclase  ↑ cAMP → PKA → CREB  GLP1R, GLP2R
Gi/oInhibits adenylyl cyclase↓ cAMP, activates PI3K, ERK  α₂-Adrenergic
Gq/11Phospholipase CβIP₃/DAG → Ca²⁺ → PKC  α₁-Adrenergic
βγ subunits Ion channels, PI3K  Cross-talk signaling  Various GPCRs

GPCR importance in human disease

Because of their critical roles in cellular signaling and their presence across nearly all tissues, GPCRs are central to the treatment of many human diseases. These receptors regulate key physiological processes such as metabolism, cardiovascular function, and neuronal activity, making them exceptionally valuable drug targets. The therapeutic relevance of GPCRs is underscored by the fact that roughly one-third of all FDA-approved drugs act through them, covering conditions as diverse as hypertension, asthma, diabetes, obesity, and neurological disorders. Advances in molecular pharmacology have also enabled the development of biased agonists and allosteric modulators, which fine-tune receptor signaling to achieve more specific therapeutic effects while minimizing side effects. This versatility has cemented GPCRs as one of the most successful and continuously expanding classes of drug targets in modern medicine. Among this large receptor family, the GLP-1 receptor (GLP1R) and GLP-2 receptor (GLP2R) stand out as particularly impactful examples. Drugs that activate GLP1R, such as semaglutide and tirzepatide, have revolutionized the management of type 2 diabetes and obesity, offering not only superior glycemic control but also significant cardiovascular and weight-loss benefits. Similarly, GLP2R agonists like teduglutide have provided transformative treatment options for short bowel syndrome and other forms of intestinal failure by stimulating epithelial repair and nutrient absorption. These examples highlight how understanding GPCR signaling can directly translate into life-changing therapies, illustrating the profound role of receptor pharmacology in addressing major metabolic and gastrointestinal diseases.

GLP-1, GLP-2 and their receptors

Glucagon-like peptide 1 (GLP-1) and glucagon-like peptide 2 (GLP-2) are two peptide hormones derived from the same proglucagon gene, which is processed differently depending on the tissue. In intestinal L-cells, proglucagon is cleaved by prohormone convertase 1/3 (PC1/3) to generate GLP-1 and GLP-2. Both hormones are secreted after food intake and act through distinct Gs-coupled receptors, GLP1R and GLP2R, respectively. GLP-1 acts on pancreatic β-cells to stimulate glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite through central mechanisms in the hypothalamus and brainstem. GLP-2, on the other hand, targets receptors in the intestinal mucosa, subepithelial myofibroblasts, and enteric neurons, where it promotes intestinal epithelial growth, increases villus height, enhances barrier integrity, and reduces apoptosis of mucosal cells. Both receptors activate cAMP–PKA–CREB signaling, but their expression patterns lead to distinct physiological outcomes—GLP1R primarily regulating glucose metabolism and appetite, and GLP2R driving intestinal repair and nutrient absorption.

GLP1R and GLP2R targeting drugs

Therapeutically, several GLP-1 receptor agonists have been approved to exploit these metabolic effects. Drugs such as exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide mimic or enhance GLP-1 activity, resulting in improved glycemic control, weight reduction, and cardiovascular protection in patients with type 2 diabetes or obesity. These drugs are typically long-acting analogs resistant to degradation by dipeptidyl peptidase-4 (DPP-4). By contrast, drugs targeting GLP2R focus on intestinal health. Teduglutide (marketed as Gattex® or Revestive®) is a GLP-2 analog that enhances mucosal growth and fluid absorption, approved for short bowel syndrome (SBS). Other GLP-2 analogs—apraglutide and glepaglutide—are in advanced clinical trials and aim to provide longer half-lives and improved safety profiles. Collectively, GLP1R-targeted therapies address metabolic disorders, while GLP2R agonists treat intestinal insufficiency and mucosal injury conditions.
Target / ReceptorDrug ExamplesMechanism of ActionApproved / Investigational Indications
GLP-1R agonistsExenatide, Liraglutide, Dulaglutide, Semaglutide, Tirzepatide (dual GIP/GLP-1)Mimic GLP-1 to enhance insulin secretion, reduce glucagon, slow gastric emptying, and suppress appetiteType 2 diabetes, obesity, and cardiovascular risk reduction
GLP-2R agonistsTeduglutide (Gattex® / Revestive®); Apraglutide, Glepaglutide (in clinical trials)Mimic GLP-2 to stimulate intestinal epithelial growth, enhance mucosal repair, and improve nutrient absorptionShort Bowel Syndrome (SBS), intestinal failure, and mucosal injury disorders

What MarinBio can do to help your drug program

At MarinBio, we specialize in advanced pharmacological testing platforms capable of evaluating the biological effects of both research-grade and validated GLP/GMP-level cell-based assays. Our team focuses on the study of GLP-1R and GLP-2R agonists, key therapeutic targets involved in metabolic regulation and intestinal function. By combining regulatory-compliant assay design with biologically relevant cell models, we can assess drug activity and receptor-mediated signaling with precision. This capability enables us to provide clients with high-quality preclinical data suitable for exploratory screening, IND-enabling validation, or comparative potency studies.   GLP1 dose response curve, 4PL, cAMP assay Example chart of Teduglutide biological activity measurements in MarinBio. Reference standard material is compared to test sample in a validated cell-based GMP assay. Luminescence decreases with increasing Teduglutide activity representing higher cyclic AMP generation and decreased ATP.   To measure functional responses downstream of GPCR activation, MarinBio employs Promega’s Kinase-Glo® luminescent assay, a robust platform for quantifying ATP levels as a readout of kinase activity. In the context of GLP-1R and GLP-2R studies, receptor stimulation triggers the Gs–adenylyl cyclase–cAMP signaling cascade, leading to PKA activation and increased ATP turnover. The Kinase-Glo® system detects this ATP change as luminescence, offering a sensitive and reproducible method to quantify receptor activation in real time. Through this approach, MarinBio integrates mechanistic insights with regulatory rigor—bridging discovery biology and compliance-ready assay validation for biopharmaceutical clients developing next-generation GLP receptor therapeutics. Disclaimer: This blog post is intended solely for educational and scientific informational purposes. Any mention of therapeutic drug names, including FDA-approved medications, is for the purpose of accurate reporting and discussion of biomedical research and does not constitute medical advice, endorsement, or promotion. Readers should not interpret the content as a recommendation for any specific treatment. Always consult a qualified healthcare professional for medical advice or treatment decisions.

About Marin Biologic Laboratories

Our Recent Publication/Meeting Presentation on Gene Therapy

1. Development of VNX-101, an Adeno-Associated Virus with Less Immunogenicity and Efficient Long-Term Expression of a CD19 T-Cell Engager. Molecular Therapy Methods & Clinical Development, published online July 24, 2025.

2. Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217.

3. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. bioRxiv 2025.04.15.648836v1 https://www.biorxiv.org/content/10.1101/2025.04.15.648836v1.

4. American Society of Hematology (ASH) Annual Meeting 2024. Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline. Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.  
 

Download the full presentation: Development of Custom Cell Based and In vitro Potency and Pharmacokinetics (PK) Assays for AAV vectors- Marin biologic Laboratories

 

Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)

 

Drug Discovery & Development Assays Offered by Marin Biologic Laboratories (MarinBio)